Aristotle

Greatman

Aristotle (born 384 BCE, Stagira, Chalcidice, Greece—died 322, Chalcis, Euboea) ancient Greek philosopher and scientist, one of the greatest intellectual figures of Classical antiquity and Western history. He was the author of a philosophical and scientific system that became the framework and vehicle for both Christian Scholasticism and medieval Islamic philosophy. Even after the intellectual revolutions of the Renaissance, the Reformation, and the Enlightenment, Aristotelian concepts remained embedded in Western thinking.

Socrates

Greatman

Socrates was a widely recognized and controversial figure in his native Athens, so much so that he was frequently mocked in the plays of comic dramatists.

Plato

Greatman

Plato (born 428/427 BCE, Athens, Greece—died 348/347, Athens) ancient Greek philosopher, student of Socrates (c. 470–399 BCE), teacher of Aristotle (384–322 BCE), and founder of the Academy, best known as the author of philosophical works of unparalleled influence. He is one of the major figures of Classical antiquity.

Scientific Advisory Board​

Xiaodong Wang, Ph.D.

  • Founding Director of National Institute of Biological Sciences, Beijing
  • Co-founder and Chairman of SAB of BeiGene
  • Member of the National Academy of Sciences, USA
  • Foreign member of the Chinese Academy Sciences
  • HHMI Investigator

Williamson Bradford, M.D., Ph.D.

  • Former SVP, Clinical Development at InterMune, the originator of Esbriet® (Pirfenidone)
  • Co-founder and CMO of Indalo Therapeutics
  • More than 20 years of industry experience leading innovative drug development, including executive, clinical development, board roles, and expertise in the development of therapeutics in pulmonary fibrosis

Scott Seiwert, Ph.D.

  • Former SVP of Research and Technical Development and Executive Committee member of InterMune
  • Co-founder and CSO of Indalo Therapeutics
  • More than 20 years of extensive experience in the management of cross functional teams consisting of drug discovery, non-clinical, CMC, and early clinical development

Toby Maher, M.D., Ph.D.

  • Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California
  • Specializing in the management of all forms of pulmonary fibrosis
  • Research interests include basic and translational research into IPF, with a major focus on biomarker discovery, early phase clinical trials, and the pre-clinical validation of putative targets and compound for the treatment of fibrosing lung disease
滚动至顶部